Novartis Swings Back At Mylan In Blood Transfusion IP Row
Novartis swung a counterpunch in its fight with Mylan over its plans to sell a generic version of its blood transfusion drug, arguing that Novartis' prior participation in Europe's "orphan" drug...To view the full article, register now.
Already a subscriber? Click here to view full article